Showing results (121-130 of 143) with videos related to
Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.NPJ Breast Cancer|September 10, 2021
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancerAmanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, et al.Scientific Reports|July 3, 2020
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancerLidia Delrieu, Emmanuelle Jacquet, Céline Segura-Ferlay, et al.The Lancet. Oncology|October 19, 2016
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trialOlivier Mir, Thomas Brodowicz, Antoine Italiano, et al.British Journal of Cancer|November 17, 2025
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trialValérie Laurence, Nina Jehanno, Sylvain Dureau, et al.The Pediatric Infectious Disease Journal|October 9, 2024
Antiviral Treatment and Risk of Hearing Loss in Asymptomatic and Mild Symptomatic Infants With Congenital CytomegalovirusSerena Villaverde, Roberto Pedrero-Tomé, Vassiliki Papaevangelou, et al.Journal of Immunological Methods|May 18, 2017
Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodiesAna Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, Jordana Grazziela Coelho-Dos-Reis, et al.Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.Pageof 15